Ancora Heart Announces Key Activities for Transcatheter Cardiovascular Therapeutics 2018

Published: Sep 10, 2018

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced the company’s key activities at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation in San Diego.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180910005302/en/

Interim data will be presented from the recently expanded U.S. early feasibility study evaluating the safety of the investigational AccuCinch® Ventricular Repair System designed for the treatment of heart failure and functional mitral regurgitation (FMR).

Ancora Heart’s primary TCT conference activities include:

Saturday, September 22

  • Didactic Session: Interventional Heart Failure and Hemodynamic Support, Part 1, Percutaneous Ventricular Reshaping of the LV for Chronic Heart Failure: Ancora
  • Presented by Daniel Burkhoff, M.D. at 11:44 am in Room 6D, Upper Level

Sunday, September 23

  • Didactic Session: Transcatheter Mitral Valve Therapies, Part 1 - Mitral Valve Repair, AccuCinch Basal Ventriculoplasty for Functional MR and Heart Failure: Device, Procedure, and Updated Outcomes
  • Presented by Mark Reisman, M.D. at 5:05 pm in Room 1, Upper Level

Ancora Heart’s AccuCinch therapy has the potential to treat heart failure and FMR patients in whom the disease has progressed beyond the ability for medications and pacemakers to manage symptoms or for whom the risks of open-heart surgery are too high. Unlike current technologies that replicate surgical procedures to replace or repair an otherwise-normal mitral valve, AccuCinch is designed to repair the left ventricle directly to address the fundamental cause of heart failure.

About Ancora Heart

Ancora Heart, Inc., based in Santa Clara, Calif., is dedicated to helping people with heart failure feel better and live longer. Ancora Heart has developed the AccuCinch System, an investigational therapy designed to repair the enlarged left ventricle targeting the underlying cause of heart failure. The AccuCinch heart failure treatment was created to benefit the millions of patients who otherwise have no minimally invasive option available to them. For more information visit www.ancoraheart.com.

 

Contacts

Ancora Heart:
Bart Beasley, 408-727-1105
bbeasley@ancoraheart.com
or
Media Contact for Ancora Heart:
Sierra Smith, 408-540-4296
sierra@healthandcommerce.com

 
 

Source: Ancora Heart, Inc.

Back to news